Edwards Lifesciences Corporation (EW) has been observing several changes lately. EW registered a decline of 19.2% in short interest in December. Recent insider trades suggest a strong buy-in from key players. Financial firms, including Ninety One UK Ltd and Ninety One North America Inc., have purchased substantial shares in EW. However, a reported US$1.5b decrease in market cap last week has impacted institutional investors. Despite this, the company holds a 'Moderate Buy' recommendation from analysts due to its proven financials and strong growth potential.
EW stock is outperforming the healthcare sector overall. Although there are fluctuations in shareholdings, recent acquisitions by groups like Hudson Bay Capital Management LP and Bank of Nova Scotia attest to the strong belief in its growth potential. Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System has received FDA approval, cementing EW's place in the medical device market. Additionally, robust TAVR growth is likely to drive EW's Q3 earnings.
Ahead of the company's Q3 earnings report, the stock retains a bullish prospect, based on strong sales growth and upgraded guidance. EW is set to host an earnings conference call on October 30, 2025, and analysts expect positive results.
Edwards Lifesciences Corp EW News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Fri, 02 Jan 2026 18:51:06 GMT - Rating 5 - Innovation 8 - Information 9 - Rumor 2
